Evidence map›Paper›PMID 20691043›Full record

ArticleBreast cancer research : BCR2010

Columnar cell lesions and subsequent breast cancer risk: a nested case-control study.

Sarah A Aroner, Laura C Collins, Stuart J Schnitt, James L Connolly, Graham A Colditz, Rulla M Tamimi

Open access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 61 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. How Do We Approach Benign Proliferative Lesions?Current oncology reports · 2018
    Review
  11. Observational
  12. Article
  13. Article
  14. Management of flat epithelial atypia on breast core biopsy may be individualized based on correlation with imaging studies.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2015
    Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Sarah A AronerDepartment of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA. sarah.aroner@channing.harvard.edu
Laura C Collins
Stuart J Schnitt
James L Connolly
Graham A Colditz
Rulla M Tamimi
Harvard University · USBeth Israel Deaconess Medical Center · USWashington University in St. Louis · US

Funding

Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI TWOROGER, SHELLEY S · 2000 to 2019
$77.8M
Risk Factors for Breast Cancer in Younger NursesR01CA050385 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI ELIASSEN, A. HEATHER, WILLETT, WALTER C. · 1989 to 2019
$32.3M
Variation in Receptor Tyrosine Kinases and Breast Cancer RiskP50CA089393 · NCI · DANA-FARBER CANCER INSTITUTE · PI HARRIS, LYNDSAY NORINE · 2000 to 2009
$28.8M
BENIGN BREAST DISEASE &RISK OF BREAST CANCERR01CA046475 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI TAMIMI, RULLA M · 1987 to 2009
$3.1M
NCI NIH HHS CA046475NCI NIH HHS CA050385NCI NIH HHS CA087969NCI NIH HHS CA089393NCI NIH HHS R01 CA046475
6 · The paper itself

Abstract

introductionHistologic and genetic evidence suggests that at least some columnar cell lesions (CCL) of the breast represent precursor lesions in the low-grade breast neoplasia pathway. However, the risk of subsequent breast cancer associated with the presence of CCL in a benign breast biopsy is poorly understood.

methodsThe authors examined the association between the presence of CCL and subsequent breast cancer risk in a nested case-control study of benign breast disease (BBD) and breast cancer within the Nurses' Health Studies (394 cases, 1,606 controls). Benign breast biopsy slides were reviewed by pathologists and CCL presence assessed. Logistic regression was used to compute odds ratios (ORs) and 95% confidence intervals (CIs) for the association between CCL and breast cancer risk.

resultsWomen with CCL (140 cases, 448 controls) had an increased risk of breast cancer compared with those without CCL (OR = 1.44, 95% CI: 1.14 to 1.83), although this was attenuated and became non-significant after adjustment for the histologic category of BBD (OR = 1.20, 95% CI: 0.94 to 1.54). CCL presence was associated with the greatest risk of breast cancer for those with nonproliferative BBD (OR = 1.36, 95% CI: 0.79 to 2.37) and the lowest risk for those with atypical hyperplasia (AH) (OR = 1.10, 95% CI: 0.65 to 1.87); however, this apparent heterogeneity in risk across BBD categories was not significant (P for interaction between CCL presence and BBD category = 0.77).

conclusionsThese results provide evidence that CCL may be an important marker of breast cancer risk in women with BBD but suggest that CCL do not increase breast cancer risk independently of concurrent proliferative changes in the breast.

Indexed as

AdultBiopsyBreastBreast DiseasesBreast NeoplasmsCase-Control StudiesFemaleHumansLogistic ModelsMiddle AgedOdds RatioPrecancerous ConditionsRisk AssessmentRisk Factors

Identifiers

PMID20691043
PMCPMC2949654
OpenAlexW2158747437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.